4 June, Preliminary Monepantel SARS-CoV-2 Data
200604_Preliminary Monepantel SARS-CoV-2 Data
May 31, Top 20 Shareholders
200602_Top_Holders_Report
12 May, Phase II Trial – Successful Anti-Cancer Outcome
200512_Phase II Trial Update – Successful Outcome
April 30, Top 20 Shareholders
200501_top20shareholders
30 April, Appendix 3G Notification of Issue, Conversion or Payment of Equity + Securities
200430_Performance rights
20 April, Appendix 4C and Quarterly Update
200420_Appendix 4C and Quarterly Update
17 April, PharmAust and WEHI evaluate monepantel for COVID-19 in vitro
200417_Monepantel in SARS-CoV-2
31 March, Top 20 Shareholders
200401_Top_Holders
31 March, Expiry of Options
200313_Expiry of Options
31 March, Phase II Trial Update
200313_Phase II Dog Trial Update